Navigation Links
Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Date:6/25/2008

proteins encoded by the polynucleotides. Vical's patent coverage includes delivery of linear DNA as well as plasmid DNA.

Currently plasmid DNA vaccines, which are under development against pandemic influenza and other infectious diseases at Vical, are manufactured by bacterial fermentation in standardized equipment with a production time measured in weeks rather than months. While plasmid DNA vaccines offer a significant improvement over conventional vaccine manufacturing technologies, the RapidResponse(TM) DNA vaccine platform could offer further advantages, especially in greater speed of production and lower cost. The company plans to continue development of its plasmid DNA vaccine programs because the technology is much closer to commercial realization in humans.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that coul
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... in Santa Ana, California is a ... market for which is estimated at $22 billion in the ... includes the use of FDA-approved Naltrexone in a specially compounded ... (excluding Australia and New ...
(Date:3/27/2015)... Across the global healthcare landscape, the Medical ... development, market education, and regulatory compliance. As emerging markets ... is expected to increase in prominence and follow the ... to research by benchmarking firm, Best Practices, LLC, all ... Medical Affairs. Among companies in India ...
(Date:3/27/2015)... March 27, 2015  The quality function within the ... products meet quality standards at every stage of the ... quality leaders also have the challenge of balancing quality ... Those who don,t effectively balance these priorities risk funding ... marketplace failure and regulatory scrutiny. For the ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... MOUNTAIN VIEW, Calif., Feb. 28, 2011 VIVUS, ... to the development and commercialization of novel therapeutic products, today ... and year ended December 31, 2010. ... development program, we successfully completed the two-year SEQUEL study, an ...
... The staffs of Chiltern International Limited (Chiltern), a global ... 25 year mark of their successful collaboration in Drug ... have worked together using a validated and regulatory accepted ... assessment of drug phototoxicity. The history of this collaboration ...
Cached Medicine Technology:VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 2VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 3VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 4VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 5VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 6VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results 7Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 2Chiltern - Spectratox Drug Photoxicity Collaboration Celebrates 25 Years 3
(Date:3/28/2015)... 28, 2015 How best to treat ... field in orthopaedic medicine. While diagnostic hip injections are ... the pain etiology, research presented today at the American ... Day suggests that pain relief from this diagnostic injection ... , “Our study looked to assess if the ...
(Date:3/28/2015)... 28, 2015 Early surgery may not ... V AC joint injuries, according to new research from ... the American Orthopaedic Society for Sports Medicine’s ( AOSSM ... faster when surgery was not performed. , The final ... surgical treatment and 17 receiving non-surgical therapy. Of the ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., has announced ... Who and the Doors played together at the Singer Bowl ... Hawley, “The Who toured the United States heavily from 1967 ... the most famous Who poster was a poster created to ... August 2, 1968 at the Singer Bowl in Flushing, New ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Aureus ... healthcare staffing, including physical therapy jobs, has announced ... the Ohio Physical Therapy Association Annual Conference to ... Columbus Downtown Hotel in Columbus, OH. , ... opportunities, and exhibits with products and services. ...
(Date:3/28/2015)... March 28, 2015 The "Petrick ... of sustainable health. After 18 years of research and ... professional UFC contenders, Dr. Jon Petrick is excited to ... Just some of the immediate benefits of this radical ... increased levels of strength of the immune system, faster ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2
... Joins International Observance To Draw Attention To "The Sneak Thief ... In an effort to combat one of the leading causes ... Glaucoma Patient Organization have set March 12, 2009, as the ... be marked by awareness and educational events organized by eye ...
... Services, Inc. (NYSE: WST ) announced today ... before the market opens on Thursday, February 19, 2009 ... the results and business expectations at 9:00 a.m. Eastern ... or (210)839-8398. The passcode is WST.A live broadcast of ...
... of New York Health AdvisoryNEW YORK, Feb. 12 ... children in New York City, according to the United ... research suggests that there are many causes for asthma ... immune system changes that result from the presence, or ...
... Available to a Wider Medical Market through Nation,s Largest GPO ... ... Medical Devices, an industry leader in infection control products, has recently ... largest and most respected GPOs, or group provider organizations. As Novation ...
... of image management services for endovascular imaging and ... made a contribution to the Open the Pathway ... the Pathway is an initiative that was established ... commitment to vascular treatment planning, post-operative patient outcomes ...
... Dynatronics Corporation (Nasdaq: DYNT ) will release ... December 31, 2008 during the morning of Friday, February ... investors later that day at 1:00 p.m. ET to ... periods. Those interested in participating should call 800-839-9416 ...
Cached Medicine News:Health News:World Glaucoma Day Set For March 12, 2009 2Health News:World Glaucoma Day Set For March 12, 2009 3Health News:World Glaucoma Day Set For March 12, 2009 4Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma 2Health News:Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma 3Health News:Inviro Medical Devices Is Awarded a Three Year Contract with Leading GPO Novation 2Health News:M2S, Inc. Makes Contribution to American Vascular Association 2Health News:M2S, Inc. Makes Contribution to American Vascular Association 3
... sophisticated research tool that allows to see ... is being stimulated. Besides it also includes ... to switch between the pupil picture and ... This system is especially suited for animal ...
The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma....
Kelly Punches...
... The CSV- lOOOHGT instrument provides standardized glare testing. ... Vectorvision test faces for the evaluation of glare ... is precisely calibrated to simulate two on-coming halogen ... feet. The glare level can be adjusted to ...
Medicine Products: